A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
Gilenya
Recommended Posts
- 2 common MS treatments show equal benefit in late-onset disease
- New MRI approach may identify active MS lesions without contrast
- New AI partnership targets earlier MS diagnosis using circular RNA
- Privosegtor optic neuritis clinical trial design gains FDA agreement
- In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS